Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 03, 2022 08:00 ET | Source: Celularity, Inc.

Celularity Appoints Industry Leader Diane Parks to its Board of Directors

FLORHAM PARK, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell...
May 18, 2022 08:30 ET | Source: Celularity, Inc.

Celularity Inc. Announces $30 Million Private Placement Priced At-The-Market Under Nasdaq Rules

FLORHAM PARK, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell...
May 16, 2022 16:10 ET | Source: Celularity, Inc.

Celularity Reports First Quarter 2022 Financial Results and Provides Corporate Update

Ongoing Phase 1 study of unmodified placental-derived natural killer (NK) cell therapy candidate, CYNK-001, in acute myeloid leukemia (AML) continues enrolling new cohorts to reflect adjustments to...
March 31, 2022 16:05 ET | Source: Celularity, Inc.

Celularity Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Two ongoing Phase 1 trials of unmodified placental-derived natural killer cell therapy candidate, CYNK-001, in acute myeloid leukemia (AML) and glioblastoma multiforme (GBM) An ongoing Phase 1...
March 15, 2022 16:05 ET | Source: Celularity, Inc.

Celularity to Present at Oppenheimer 32nd Annual Healthcare Conference

FLORHAM PARK, N.J., March 15, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic...
February 15, 2022 16:05 ET | Source: Celularity, Inc.

Celularity Receives Orphan Drug Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers

CYNK-101 is an investigational genetically modified NK cell therapy designed to synergize with antibody therapeutics for difficult to treat cancers of high unmet medical need Phase 1/2a clinical...
January 18, 2022 08:00 ET | Source: Celularity, Inc.

Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers

CYNK-101 is an investigational genetically modified natural killer (NK) cell therapy designed to synergize with antibody therapeutics for difficult to treat cancers of high unmet medical need Phase...
December 27, 2021 08:00 ET | Source: Celularity, Inc.

Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML

FLORHAM PARK, N.J., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies,...
December 13, 2021 08:00 ET | Source: Celularity, Inc.

Celularity Presents Preclinical Data on Allogeneic Genetically Modified Natural Killer (NK) and Allogeneic CAR-NK Cell Therapy Programs at the 63rd American Society of Hematology Meeting and Exposition

FLORHAM PARK, N.J., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”) presented preclinical data on the development of its placental-derived allogeneic genetically...
November 29, 2021 08:00 ET | Source: Celularity, Inc.

Celularity Announces FDA Clearance of Investigational New Drug Application (IND) for Natural Killer Cell Therapy CYNK-101 in First-line Advanced Her2/neu Positive Gastric and Gastroesophageal Junction Cancer

CYNK-101 is an investigational genetically engineered natural killer (NK) cell therapy designed to synergize with antibody therapeutics Phase 1/2a clinical trial will evaluate the safety and...